Show simple item record

dc.contributor.authorKufareva, Irina
dc.contributor.authorBestgen, Benoit
dc.contributor.authorBrear, Paul
dc.contributor.authorPrudent, Renaud
dc.contributor.authorLaudet, Béatrice
dc.contributor.authorMoucadel, Virginie
dc.contributor.authorEttaoussi, Mohamed
dc.contributor.authorSautel, Celine F
dc.contributor.authorKrimm, Isabelle
dc.contributor.authorEngel, Matthias
dc.contributor.authorFilhol, Odile
dc.contributor.authorBorgne, Marc Le
dc.contributor.authorLomberget, Thierry
dc.contributor.authorCochet, Claude
dc.contributor.authorAbagyan, Ruben
dc.date.accessioned2019-12-07T02:01:49Z
dc.date.available2019-12-07T02:01:49Z
dc.date.issued2019-11-04
dc.identifier.issn2045-2322
dc.identifier.other31685885
dc.identifier.otherPMC6828666
dc.identifier.urihttps://www.repository.cam.ac.uk/handle/1810/299618
dc.description.abstractCK2 is a constitutively active protein kinase overexpressed in numerous malignancies. Interaction between CK2α and CK2β subunits is essential for substrate selectivity. The CK2α/CK2β interface has been previously targeted by peptides to achieve functional effects; however, no small molecules modulators were identified due to pocket flexibility and open shape. Here we generated numerous plausible conformations of the interface using the fumigation modeling protocol, and virtually screened a compound library to discover compound 1 that suppressed CK2α/CK2β interaction in vitro and inhibited CK2 in a substrate-selective manner. Orthogonal SPR, crystallography, and NMR experiments demonstrated that 4 and 6, improved analogs of 1, bind to CK2α as predicted. Both inhibitors alter CK2 activity in cells through inhibition of CK2 holoenzyme formation. Treatment with 6 suppressed MDA-MB231 triple negative breast cancer cell growth and induced apoptosis. Altogether, our findings exemplify an innovative computational-experimental approach and identify novel non-peptidic inhibitors of CK2 subunit interface disclosing substrate-selective functional effects.
dc.languageeng
dc.rightsAttribution 4.0 International
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/
dc.sourcenlmid: 101563288
dc.sourceessn: 2045-2322
dc.titleDiscovery of holoenzyme-disrupting chemicals as substrate-selective CK2 inhibitors.
dc.typeArticle
dc.date.updated2019-12-07T02:01:48Z
dc.identifier.doi10.17863/CAM.46690
rioxxterms.versionofrecord10.1038/s41598-019-52141-5
rioxxterms.versionVoR
rioxxterms.licenseref.urihttps://creativecommons.org/licenses/by/4.0/
dc.contributor.orcidKufareva, Irina [0000-0001-9083-7039]
dc.contributor.orcidFilhol, Odile [0000-0003-1964-7958]
dc.contributor.orcidBorgne, Marc Le [0000-0003-1398-075X]
pubs.funder-project-idU.S. Department of Health & Human Services | NIH | National Institute of General Medical Sciences (NIGMS) (GM117424, GM074832)
pubs.funder-project-idAgence Nationale de la Recherche (French National Research Agency) (PCV08_324733)
pubs.funder-project-idNHLBI NIH HHS (R35 HL135737)
pubs.funder-project-idNIGMS NIH HHS (R01 GM074832, R01 GM117424)
pubs.funder-project-idInstitut National Du Cancer (French National Cancer Institute) (No 57, 2011-097)
pubs.funder-project-idNIAID NIH HHS (R01 AI118985)
pubs.funder-project-idNINDS NIH HHS (R01 NS102432)
pubs.funder-project-idU.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases (NIAID) (AI118985)
pubs.funder-project-idRégion Auvergne-Rhône-Alpes (Region Auvergne-Rhône-Alpes) (ARC 1 Santé 12-008707-01)


Files in this item

Thumbnail
Thumbnail
Thumbnail
Thumbnail

This item appears in the following Collection(s)

Show simple item record

Attribution 4.0 International
Except where otherwise noted, this item's licence is described as Attribution 4.0 International